MB ChB, MRCP, FRCPath, MD
Haematology, Myeloma, Stem cell transplantation
- Member of the NCRN AML working group
- Member of British Society for Haematology
- Member of the European Haematology Association
- Member of the American Society of Haematology
- Member of the European group for Blood and Marrow Transplantation
Mike Dennis qualified in Medicine from the University of Dundee in 1991, completed his physician's training in Liverpool before undertaking his first Haematology post in Perth, Australia. He returned to the UK and his first appointment at The Christie in 1996 and then completed his Haematology training, including a MD from the University of Liverpool. He was appointed consultant haematologist at The Christie in 2004. Since then, he has been clinical director for the haematology and transplant unit (2004-2014) and haematological cancer pathway director for Manchester Cancer (2014-2017).
His clinical practice involves the management of patients with all myeloid disease which require chemotherapy, trials and transplantation.
He is an established expert in acute myeloid leukaemia (AML), a committee member of the NCRN working group for AML, where his roles include Chief investigator (Li1) and Co-chief investigator (AML 19) premier front line trials in AML.
He frequently performs as clinical expert for NICE technology appraisals in AML and is a regular invited speaker on AML nationally and internationally.
Getting the best possible outcome for AML patients is his primary focus.
His research is in clinical trial development for optimal therapy in AML of traditional and emerging agents, from site development and delivery of phase 1 studies to international trial governance.
The Christie Private Care
Dr. Dennis also practises privately at The Christie Private Care